On Monday, Summit Therapeutics Inc (NASDAQ: SMMT) was 5.11% up from the session before settling in for the closing price of $18.99. A 52-week range for SMMT has been $1.64 – $33.89.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales slid by -28.65% over the last five years. When this article was written, the company’s average yearly earnings per share was at 69.54%. With a float of $112.90 million, this company’s outstanding shares have now reached $701.66 million.
The firm has a total of 105 workers. Let’s measure their productivity. In terms of profitability, gross margin is 385.96%, operating margin of 77338.72%, and the pretax margin is 83760.85%.
Summit Therapeutics Inc (SMMT) Insider Activity
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Summit Therapeutics Inc stocks. The insider ownership of Summit Therapeutics Inc is 84.68%, while institutional ownership is 10.07%. The most recent insider transaction that took place on Mar 27 ’24, was worth 201,874. In this transaction Chief Executive Officer of this company bought 54,321 shares at a rate of $3.72, taking the stock ownership to the 24,923,800 shares. Before that another transaction happened on Mar 26 ’24, when Company’s Chief Executive Officer bought 30,000 for $3.75, making the entire transaction worth $112,500. This insider now owns 30,000 shares in total.
Summit Therapeutics Inc (SMMT) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.08 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 69.54% per share during the next fiscal year.
Summit Therapeutics Inc (NASDAQ: SMMT) Trading Performance Indicators
You can see what Summit Therapeutics Inc (SMMT) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 8.31.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.28, a number that is poised to hit -0.08 in the next quarter and is forecasted to reach -0.38 in one year’s time.
Technical Analysis of Summit Therapeutics Inc (SMMT)
Analysing the last 5-days average volume posted by the [Summit Therapeutics Inc, SMMT], we can find that recorded value of 2.55 million was lower than the volume posted last year of 3.65 million. As of the previous 9 days, the stock’s Stochastic %D was 22.58%. Additionally, its Average True Range was 1.79.
During the past 100 days, Summit Therapeutics Inc’s (SMMT) raw stochastic average was set at 48.62%, which indicates a significant increase from 28.85% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 97.21% in the past 14 days, which was lower than the 118.25% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $20.10, while its 200-day Moving Average is $9.71. Now, the first resistance to watch is $20.75. This is followed by the second major resistance level at $21.53. The third major resistance level sits at $22.51. If the price goes on to break the first support level at $18.99, it is likely to go to the next support level at $18.01. Should the price break the second support level, the third support level stands at $17.23.
Summit Therapeutics Inc (NASDAQ: SMMT) Key Stats
There are 737,448K outstanding shares of the company, which has a market capitalization of 14.71 billion. As of now, sales total 0 K while income totals -614,930 K. Its latest quarter income was 0 K while its last quarter net income were -60,390 K.
